ScholarIQanswers from OpenAlex & ORCID
Siraj M. Ali
ResearcherPublications, citations & collaboration network
Siraj M. Ali is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Siraj M. Ali have?
ScholarIQindexed works
Siraj M. Ali has 802 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Siraj M. Ali have?
ScholarIQcitation count
Siraj M. Ali has 49,868 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Siraj M. Ali?
ScholarIQh-index
Siraj M. Ali has an h-index of 95 in OpenAlex.
What is the i10-index of Siraj M. Ali?
ScholarIQi10-index
Siraj M. Ali has an i10-index of 306 in OpenAlex.
What is the ORCID of Siraj M. Ali?
ScholarIQorcid
The ORCID for Siraj M. Ali is on the source record.
What is the OpenAlex record for Siraj M. Ali?
ScholarIQopenalex
The OpenAlex for Siraj M. Ali is on the source record.
What are the most-cited papers on Siraj M. Ali?
ScholarIQmost cited works
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio, Laurie M. Gay, Siraj M. Ali, Riley Ennis, Alexa B. Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin W. Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi A. Garraway, Vincent A. Miller, P. J. Stephens, Garrett M. Frampton
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie M. Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Péter M. Szabó, Chang Han, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph D. Szustakowski, Patrik Vitazka, Robin Edwards, José A. Bufill, Neelesh Sharma, Sai‐Hong Ignatius Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jiménez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galán‐Cobo, Haïfa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez‐Canales, Pamela Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino–Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok‐Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M. Bauer, Mikhail Akimov, José A. Bufill, Carrie B. Lee, David Jentz, Rick Hoover, Sai‐Hong Ignatius Ou, Ravi Salgia, Timothy J. Brennan, Zachary R. Chalmers, Savina Jaeger, Alan Huang, Julia A. Elvin, Rachel Erlich, Alex Fichtenholtz, Kyle Gowen, Joel Greenbowe, Adrienne Johnson, Depinder Khaira, Caitlin McMahon, Eric M. Sanford, Steven Roels, Jared White, Joel Greshock, Robert Schlegel, Doron Lipson, Roman Yelensky, Deborah Morosini, Jeffrey S. Ross, Eric A. Collisson, Malte Peters, Philip J. Stephens, Vincent A. Miller
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B. Johnson, Garrett M. Frampton, Matthew J. Rioth, Erik Yusko, Yaomin Xu, Xingyi Guo, Riley Ennis, David Fabrizio, Zachary R. Chalmers, Joel Greenbowe, Siraj M. Ali, Sohail Balasubramanian, James Sun, Yuting He, Dennie T. Frederick, Igor Puzanov, Justin M. Balko, Justin Cates, Jeffrey S. Ross, Catherine Sanders, Harlan Robins, Yu Shyr, Vincent A. Miller, Philip J. Stephens, Ryan J. Sullivan, Jeffrey A. Sosman, Christine M. Lovly
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim M. Hirshfield, Sherri Damare, Katherine Lane, Levi Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman, Siraj M. Ali, Jeffrey S. Ross, Dean C. Pavlick, Gyan Bhanot, Eileen White, Robert S. DiPaola, Ann Lovell, Jonathan D. Cheng, Shridar Ganesan